AstraZeneca: COPD treatment meets trial goal
(CercleFinance.com) - AstraZeneca said its triple-combination bronchodilator Breztri Aerosphere has met its primary endpoint in a late-stage trial, which has sent the biopharmaceutical company's shares up slightly in London.
The Phase III trial met its primary endpoint in chronic obstructive pulmonary disease (COPD) by showing a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies, the drugmaker said.
The study enrolled more than 8,500 patients who had experienced at least one moderate/severe exacerbation in the previous year and were receiving at least two inhaled maintenance treatments at entry into the trial.
AstraZeneca also said on Wednesday that the US Food and Drug Administration (FDA) has granted an "orphan drug designation" (ODD) to its Fasenra drug for the treatment of eosinophilic oesophagitis, a rare disease that occurs when eosinophils, a type of white blood cell, accumulates in the oesophagus causing injury and inflammation.
The AstraZeneca share is currently up 0.4% in London.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Phase III trial met its primary endpoint in chronic obstructive pulmonary disease (COPD) by showing a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies, the drugmaker said.
The study enrolled more than 8,500 patients who had experienced at least one moderate/severe exacerbation in the previous year and were receiving at least two inhaled maintenance treatments at entry into the trial.
AstraZeneca also said on Wednesday that the US Food and Drug Administration (FDA) has granted an "orphan drug designation" (ODD) to its Fasenra drug for the treatment of eosinophilic oesophagitis, a rare disease that occurs when eosinophils, a type of white blood cell, accumulates in the oesophagus causing injury and inflammation.
The AstraZeneca share is currently up 0.4% in London.
Copyright (c) 2019 CercleFinance.com. All rights reserved.